Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-11-03
2009-08-11
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S405000, C548S247000, C548S373100
Reexamination Certificate
active
07572797
ABSTRACT:
The present invention relates to compounds of the formulaand pharmaceutically acceptable salts and solvates thereof, to processes for the preparation of, intermediates used in the preparation of, and compositions containing such compounds and the uses of such compounds for the treatment of pain.
REFERENCES:
patent: WO 98/38174 (1998-09-01), None
patent: WO 03/045924 (2003-06-01), None
patent: WO 03/051366 (2003-06-01), None
Akopian, et al., “The Tetrodtoxin-resistant Sodium Channel SNS has a Specialized Function in Pain Pathways” Nature Neuroscince, 1999, pp. 541-548, vol. 2, No. 6.
Akopian, et al., “a Tetrodtoxin-resistant Voltage-gated Sodium Channel Expressed by Sensory Neurons”, Nature, 1996, pp. 257-262, vol. 379.
Black, et al., “Sensory Neuron-Specific Sodium Channel SNS is Abnormally Expressed in the Brains of Mice with Experimental Allergic Encephalomyelitis and Humans with Multiple Sclerosis”, PNAS, 2000, pp. 11598-11602, vol. 97, No. 21.
Black, et al., “Abnormal expression of SNS/PN3 Sodium Channel in Cerebellar Purkinje Cells Following Loss of Myelin in the Taiep Rat”, NeuroReport, 1999, pp. 913-918, vol. 10.
Bucknill, et al., “Nerve Finers in Lumbar Spine Structures and Injured Spinal Roots Express the Sensory Neuron=Specific Sodium Channels SNS/PN3 and NaN/SNS2”, Spine, 2002, pp. 135-140, vol. 27, No. 2.
Coward, et al., :Immunolocalization of SNS/PN3 and NaN/SNS2 Sodium Channels in Human Pain States, Pain, 2000, pp. 41-50, vol. 85, No. 1-2.
Lai, et al., “Inihibition of Neuropathic Pain by Decreased Expression of the Tetrodotoxin-resistant Sodium Channel, NaV1.8”, Pain, 2002, pp. 143-152, vol. 95.
Laird, et al., “Deficits in Visceral Pain and Referred Hyperalgesia in Nav1.8 (SNS/PN3)-Null Mice”, J Neuroscience, 2992, pp. 8352-8356, vol. 22, No. 19.
Rabert, et al., “A Tetrodotoxin-resistant Voltage-gated Sodium Channel from Human Dorsal Root Ganglia, hPN3/SCN 10A”, Pain, 1998, pp. 107-114, vol. 78, No. 2.
Shembalker, et al., “Increased Sodium Channel SNS/PN3 Immunoreactivity in a Causalgic Finger”, Euro J Pain, 2001 pp. 319-323, vol. 5, No. 3.
Yiangou, et al., “SNS/PN3 and SNS2/NaN Sodium Channel-like Immunoreactivity in Human Adult and Neonate Injured Sensory Nerves”, FEBS Letters, 2000, pp. 249-252, vol. 467, No. 2-3.
Denton Stephen Mark
Gibson Karl Richard
Glossop Melanie Susanne
Kemp Mark Ian
Poinsard Cedric
Benson Gregg C.
McDowell Brian
Olson A. Dean
Pfizer Inc.
Wilson James O
LandOfFree
Amino substituted pyrazine derivatives for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Amino substituted pyrazine derivatives for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amino substituted pyrazine derivatives for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4130022